US2010247498A1PendingUtilityA1

In vitro micro-organs, and uses related thereto

37
Individually held — no corporate assignee on recordPriority: Jan 9, 1998Filed: Feb 4, 2010Published: Sep 30, 2010
Est. expiryJan 9, 2018(expired)· nominal 20-yr term from priority
Inventors:Eduardo Mitrani
A61M 1/34A61M 1/1678A61M 1/3489
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of delivering a gene product to a recipient, the method comprises (a) providing a micro-organ explant expressing at least one recombinant gene product, the micro-organ explant comprising a population of cells, the micro-organ explant maintaining a microarchitecture and a three dimensional structure of an organ from which it is obtained and at the same time having dimensions selected so as to allow diffusion of adequate nutrients and gases to cells in the micro-organ explant and diffusion of cellular waste out of the micro-organ explant so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of the to waste in the micro-organ explant, at least some of the cells of the population of cells of the micro-organ explant expressing at least one recombinant gene product; and (b) implanting the micro-organ explant in the recipient.

Claims

exact text as granted — not AI-modified
1 . A method of delivering a gene product to a recipient, said method comprising the steps of: (a) providing a micro-organ explant expressing at least one recombinant gene product, said micro-organ explant comprising a population of cells, said micro-organ explant maintaining a microarchitecture and a three-dimensional structure of an organ from which it is obtained and at the same time having dimensions selected so as to allow diffusion of adequate nutrients and gases to cells in said micro-organ explant and diffusion of cellular waste out of said micro-organ explant so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of the waste in said micro-organ explant, at least some of the cells of said population of cells expressing at least one recombinant gene product, wherein said organ is selected from the group consisting of a lymph organ, a pancreas, a liver, a gallbladder, a kidney, a digestive tract organ, gut, a bile duct, a duodenum, a respiratory tract organ, a lung, an esophagus, a reproductive organ, a prostate, a uterus, a mammary gland, a urinary tract organ, a bladder, a kidney, a cornea, a blood-associated organ, bone marrow, a thymus and a spleen; and (b) implanting said micro-organ explant in a recipient. 
     
     
         2 . The method of  claim 1 , wherein said micro-organ explant is derived from said recipient. 
     
     
         3 . The method of  claim 1 , wherein said micro-organ explant is derived from said_donor subject. 
     
     
         4 . The method of  claim 1 , wherein said micro-organ explant is derived from a human being. 
     
     
         5 . The method of  claim 1 , wherein said micro-organ explant is derived from a non-human animal. 
     
     
         6 . The method of  claim 1 , wherein said recipient is a human being. 
     
     
         7 . The method of  claim 1 , wherein said recipient is a non-human animal. 
     
     
         8 . The method of  claim 1 , wherein said at least one recombinant gene product is selected from the group consisting of a recombinant protein and a recombinant functional RNA molecule. 
     
     
         9 . The method of  claim 8 , wherein said recombinant protein is normally produced by the organ from which the micro-organ explant is derived. 
     
     
         10 . The method of  claim 8 , wherein said recombinant protein is normally not produced by the organ from which the micro-organ explant is derived. 
     
     
         11 . The method of  claim 8 , wherein said recombinant protein is selected from the group consisting of a protease, a lipase, a ribonuclease, a deoxyribonuclease, a blood clotting factor, a cytochrome p450 enzyme, a transcription factor and a MHC component. 
     
     
         12 . The method of  claim 8 , wherein said recombinant protein is selected from the group consisting of a peptide, a glycoprotein and a lipoprotein. 
     
     
         13 . The method of  claim 8 , wherein said recombinant protein is selected from the group consisting of insulin, trypsinogen, chymotrypsinogen, carboxypeptidase, triacylyglycerol lipase, phospholipase A 2 , elastase, amylase, UDP glucuronyl transferase, ornithine transcarbanoylase, adenosine deaminase, serum thymic factor, thymic humoral factor, thymopoietin, thymosin α 1 , gastrin, secretin, cholecystokinin, somatostatin, substance P and growth hormone. 
     
     
         14 . The method of  claim 1 , wherein said genetically modified micro-organ explant is maintainable in culture for at least about twenty-four hours. 
     
     
         15 . The method of  claim 1 , wherein said micro-organ explant has a surface area to volume index characterized by the formula 1/x+1/a>1.5 mm −1 ; wherein ‘x’ is a tissue thickness and ‘a’ is a width of said tissue in millimeters. 
     
     
         16 . The method of  claim 1 , wherein said micro-organ explant comprises epithelial and connective tissue cells. 
     
     
         17 . The method of  claim 1 , wherein said organ is a pancreas, and said population of cells includes islets of Langerhans. 
     
     
         18 . The method of  claim 1 , wherein said micro-organ explant is maintainable in a minimal medium. 
     
     
         19 . The method of  claim 1 , wherein said micro-organ explant is maintainable in an artificial medium. 
     
     
         20 . The method of  claim 1 , wherein said micro-organ explant is maintainable in a defined medium. 
     
     
         21 . The method of  claim 1 , wherein at least a portion of said population of cells is transduced, transformed or transfected with a recombinant construct carrying a recombinant gene encoding said recombinant gene product. 
     
     
         22 . The method of  claim 21 , wherein said recombinant construct is a virus vector selected from the group consisting of a recombinant hepatitis virus, a recombinant adeno virus, a recombinant adeno-associated virus, a recombinant papilloma virus, a recombinant retrovirus, a recombinant cytomegalovirus and a recombinant simian virus. 
     
     
         23 . The method of  claim 21 , wherein said recombinant construct is a naked nucleic acid molecule. 
     
     
         24 . The method of  claim 1 , wherein at least a portion of the population of cells are transformed with a foreign nucleic acid sequence via a transformation method selected from the group consisting of calcium-phosphate mediated transfection, DEAE-dextran mediated transfection, electroporation, liposome-mediated transfection, direct injection, and receptor-mediated uptake. 
     
     
         25 . The method of  claim 1 , further comprising the step of encapsulating said micro-organ explant prior to said step (b). 
     
     
         26 . The method of  claim 1 , wherein said step (a) is effected by obtaining said micro-organ from an organ of a transgenic animal expressing said recombinant gene product.

Join the waitlist — get patent alerts

Track US2010247498A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.